The Estrogen Replacement and Atherosclerosis (ERA) Study: Study design and baseline characteristics of the cohort

Controlled Clinical Trials

Volumn 21, Issue 3, 2000, Pages 257-285

  Herrington, David M ^a   Reboussin, David M ^b   Klein, Karen Potvin ^a   Sharp, Penny C ^c   Shumaker, Sally A ^b   Snyder, Thomas E ^d   Geisinger, Kim R ^e  

^a Division of Internal Medicine/Cardiology   (United States)

^b Public Health Sciences   (United States)

^c Family and Community Medicine   (United States)

^d Department of Obstetrics and Gynecology   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary angiography; Estrogen replacement therapy; Postmenopause; Randomized controlled trials; Women's health

Indexed keywords

CONJUGATED ESTROGEN; GLYCERYL TRINITRATE; LIPID; LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; EXERCISE; FEMALE; GLUCOSE METABOLISM; HEALTH; HEMOSTASIS; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METHODOLOGY; MULTICENTER STUDY; POSTMENOPAUSE; QUALITY OF LIFE; QUANTITATIVE ASSAY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SMOKING HABIT; VASCULAR ENDOTHELIUM;

AGED; ARTERIOSCLEROSIS; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MEDROXYPROGESTERONE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS; QUALITY OF LIFE; RESEARCH DESIGN; SMOKING; TREATMENT OUTCOME;

EID: 0034022884     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00054-4     Document Type: Article

References (63)

1. Fuster V. Epidemic of cardiovascular disease and stroke. the three main challenges Circulation. 99:1999;1132-1137.
2. Stampfer M.J., Willett W.C., Colditz G.A.et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 313:1985;1044-1049.
3. Petitti D.B., Perlman J.A., Sidney S. Noncontraceptive estrogens and mortality. long-term follow-up of women in the Walnut Creek study Obstet Gynecol. 70:1987;289-293.
4. Bush T.L., Barrett-Connor E., Cowan L.D.et al. Cardiovascular mortality and noncontraceptive use of estrogen in women. results from the Lipid Research Clinics Program Follow-up Study Circulation. 75:1987;1102-1109.
5. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 94:1987;620-625.
6. Henderson B.E., Ross R.K., Lobo R.A., Pike M.C., Mack T.M. Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril. 49(5 Suppl 2):1988;9S-15S.
7. Avila M.H., Walker A.M., Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology. 1:1990;128-133.
8. Bush T.L. The epidemiology of cardiovascular disease in postmenopausal women. Ann N Y Acad Sci. 592:1990;263-271.
9. Stampfer M.J., Colditz G.A., Willett W.C.et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med. 325:1991;756-762.
10. Grady D., Rubin S.M., Petitti D.B.et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
11. Bush T.L., Fried L.P., Barrett-Connor E. Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem. 34:1988;B60-B70.
12. Sullivan J.M., Vander Zwaag R., Hughes J.P.et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med. 150:1990;2557-2562.
13. Hulley S., Grady D., Bush T.et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
14. Miller A.B. Risk/benefit considerations of antiestrogen/estrogen therapy in healthy postmenopausal women. Prev Med. 20:1991;79-85.
15. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 273:1995;199-208.
16. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 17:1997;217-221.
17. Barrett-Connor E., Wingard D.L., Criqui M.H. Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. JAMA. 261:1989;2095-2100.
18. Nabulsi A.A., Folsom A.R., White A.et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 328:1993;1069-1075.
19. Psaty B.M., Heckbert S.R., Atkins D.et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 154:1994;1333-1339.
20. Grodstein F., Stampfer M.J., Manson J.E.et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
21. Sidney S., Petitti D.B., Quesenberry C.P. Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med. 127:1997;501-508.
22. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 19:1998;61-109.
23. Grady D., Applegate B., Bush T.et al. The Heart and Estrogen/Progestin Replacement Study. Design, methods and baseline characteristics Control Clin Trials. 19:1998;314-335.
24. Simon R.J. Restricted randomized designs in clinical trials. Biometrics. 35:1979;503-512.
25. Anonymous Hormone replacement therapy. ACOG Technical Bulletin Number 166 - April 1992. Int J Gynecol Obstet. 41:1993;194-202.
26. Fan L., Jariel I., Herrington D.M. A spatiotemporal strategy for automated analysis of vasodilator response. Comput Cardiol. 25:1998;161-164.
27. Herrington D.M., Werbel B.L., Riley W.A., Pusser B.E., Morgan T.M. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol. 33:1999;2030-2037.
28. Leung W.H., Sanders W., Alderman E.L. Coronary artery quantitation and data management system for paired angiograms. Cathet Cardiovasc Diagn. 24:1991;121-134.
29. Haskell W.L., Alderman E.L., Fair J.M.et al. Atherosclerosis in coronary heart disease. effects of multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease - the Stanford Coronary Risk Intervention Project (SCRIP) Circulation. 89:1994;975-980.
30. Lees R.S., Pitt B., Chan R.C.et al. Baseline clinical and angiographic data in the Quinapril Ischemic Event trial (QUIET). Am J Cardiol. 78:1996;1011-1016.
31. Adams M.R., Kaplan J.R., Manuck S.B.et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 10:1990;1051-1057.
32. Herrington D.M., Braden G.A., Williams J.K., Morgan T.M. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol. 73:1994;951-952.
33. Celermajer D.S., Sorensen K.E., Gooch V.M.et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
34. Dipietro L., Caspersen C.J., Ostfeld A.M., Nadel E.R. A survey of assessing physical activity among older adults. Med Sci Sports Exerc. 25:1993;628-642.
35. Willett W.C., Sampson L., Stampfer M.J.et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 122:1985;51-65.
36. Rimm E.B., Stampfer M.J., Ascherio A.et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 328:1993;1450-1456.
37. Stampfer M.J., Hennekens C.H., Manson J.E.et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 328:1993;1444-1449.
38. Wenger N.K. Gender, coronary artery disease, and coronary bypass surgery. Ann Intern Med. 112:1990;557-558.
39. Shumaker S.A., Czajkowski S.M. Social support and cardiovascular disease. 1993;Plenum Press, New York.
40. McHorney C.A., Ware J.E.J., Lu W.F., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups Med Care. 32:1994;40-66.
41. Sherbourne C.D., Stewart A. The MOS Social Support Survey. Soc Sci Med. 32:1991;705-714.
42. Radloff L.S. The CES-D scale. a self-report depression scale for research in the general population Appl Psychol Meas. 1:1977;1385-1401.
43. Berkman L.F., Syme S.L. Social networks, host resistance, and mortality. a nine-year follow-up study of Alameda County residents Am J Epidemiol. 109:1979;186-204.
44. Second Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation. 89:1994;1329-1445.
45. Blankenhorn D.H., Nessim S.A., Johnson R.L.et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 257:1987;3233-3240.
46. Brown B.G., Albers J.J., Fisher L.D.et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298.
47. Buchwald H., Varco R.L., Matts J.P.et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 323:1990;946-955.
48. Ornish D., Brown S.E., Schweritz L.W.et al. Can lifestyle changes reverse coronary heart disease? Lancet. 336:1990;129-133.
49. Schuler G., Hambrecht R., Schlierf G.et al. Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet. J Am Coll Cardiol. 19:1992;34-42.
50. Arntzenius A.C., Kromhout D., Barth J.D.et al. Diet, lipoproteins, and the progression of coronary artery atherosclerosis. the Leiden Intervention Trial N Engl J Med. 312:1985;805-811.
51. Demer L.L., Gould K.L., Goldstein R.A.et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative angiography in 193 patients. Circulation. 79:1989;825-835.
52. Waters D., Craven T.E., Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 87:1993;1067-1075.
53. Buchwald H., Matts J.P., Fitch L.L.et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 268:1992;1429-1433.
54. Applegate R.J., Herrington D.M., Little W.C. Coronary angiography. more than meets the eye Circulation. 87:1993;1399-1401.
55. Reis S.E. Oestrogens attenuate abnormal coronary vasoreactivity in postmenopausal women. Ann Med. 26:1994;387-388.
56. Lieberman E.H., Gerhard M.D., Uehata A.et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
57. Gilligan D.M., Quyyumi A.A., Cannon R.O. III Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
58. Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A., Cannon R.O. III Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 75:1995;264-268.
59. Gerhard M., Walsh B.W., Tawakol A.et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 98:1998;1158-1163.
60. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 340:1999;1801-1811.
61. Williams J.K., Honoré E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 24:1994;1757-1761.
62. Sorensen K.E., Dorup I., Hermann A.P., Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation. 97:1998;1234-1238.
63. Mancini G.B.J., Henry G.C., Macaya C.et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND Study. Circulation. 94:1996;258-265.